Grifols, S.A.

GRFS · Healthcare

$7.73

Markedsværdi: 5.26B USDUdbytteafkast: +3.65%
AdvancedEr det et godt tidspunkt at købe Grifols, S.A.? Spørg Copenvest AIFå et Advanced AI-bud på timing, risiko og hvad tracked investorer gør.Spørg Copenvest AI

Indlæser diagram…

Nyheder

Seneste overskrifter for denne aktie

MT Newswires1. sep. 2026, 15.10

European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading

MT Newswires19. aug. 2026, 15.18

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires10. aug. 2026, 13.12

Grifols Completes Clinical Portion of Phase 3 Trial of Prolastin-C in Emphysema